FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events
Similar Posts
Primary Care Providers Can Prescribe with Confidence
Information and resources are available to help primary care providers manage OUD with the help of medications for opioid use disorder (MOUD).Antifungal Susceptibility Test Interpretive Criteria
Antifungal Susceptibility Test Interpretive CriteriaInnoStar Bio-Tech Nantong Company, Ltd – 11/1/2024
InnoStar Bio-Tech Nantong Company, Ltd – 11/1/2024. Country: United States. Record Type: Response to Form 483Fusion IV Pharmaceuticals Inc. dba Axia Pharmaceutical, Los Angeles, CA. 483 Issued 03/23/2017
Fusion IV Pharmaceuticals Inc. dba Axia Pharmaceutical, Los Angeles, CA. 483 Issued 03/23/2017Task Description Request Please post to the 2017 Pharmacy Inspections and Related Records Web page
Record Date 03/23/2017
FEI Number 3013341563
Firm Name Fusion IV Pharmaceuticals Inc. dba Axia PhBlendHouse. Reading, PA. EIR issued 06/09/2022
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/09/2022
Short Title (70 char) BlendHouse. Reading, PA. EIR issued 06/09/2022
FEI Number 3015728839
Firm Name BlendHouse
Record Type EIR
State PA
Establishment Type ManufacturerGlowface – 11/03/2025
Unapproved New Drugs/Misbranded/Botox